Decision aid and cost compensation influence uptake of PSA-based early detection without affecting decisional conflict: a cluster randomised trial.

Autor: Tiedje, Dorothee¹ (AUTHOR) dorothee.tiedje@ukmuenster.de, Borowski, Matthias² (AUTHOR), Simbrich, Alexandra³ (AUTHOR), Schlößler, Kathrin^4,5 (AUTHOR), Kruse, Klaus¹ (AUTHOR), Bothe, Christiane¹ (AUTHOR), Kuss, Katrin⁴ (AUTHOR), Adarkwah, Charles Christian⁴ (AUTHOR), Maisel, Peter⁶ (AUTHOR), Jendyk, Ralf⁶ (AUTHOR), Kurosinski, Marc-André³ (AUTHOR), Gerß, Joachim² (AUTHOR), Tschuschke, Christian⁷ (AUTHOR), Becker, Ralf⁸ (AUTHOR), Roobol, Monique J.⁹ (AUTHOR), Bangma, Chris H.⁹ (AUTHOR), Hense, Hans-Werner³ (AUTHOR), Donner-Banzhoff, Norbert⁴ (AUTHOR), Semjonow, Axel¹ (AUTHOR)

Publikováno v: Scientific Reports. 12/6/2021, Vol. 11 Issue 1, p1-10. 10p.

Additional file 3 of Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer

Autor: Wüstmann, Neele, Seitzer, Konstantin, Humberg, Verena, Vieler, Julia, Grundmann, Norbert, Steinestel, Julie, Tiedje, Dorothee, Duensing, Stefan, Krabbe, Laura-Maria, Bögemann, Martin, Schrader, Andres Jan, Bernemann, Christof, Schlack, Katrin

Additional file 3: Figure S3. Endogenous AR modulation using either enzalutamide treatment or a modified CRISPR/dCas9 AR activation system. A) Fold change analysis of AR-FL and AR-Vs in 22Rv1 cells treated with enzalutamide for up to 14 days. B) AR-F

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb8fc1b959a5760ae337e2b24c55cf1c

Additional file 1 of Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer

Autor: Wüstmann, Neele, Seitzer, Konstantin, Humberg, Verena, Vieler, Julia, Grundmann, Norbert, Steinestel, Julie, Tiedje, Dorothee, Duensing, Stefan, Krabbe, Laura-Maria, Bögemann, Martin, Schrader, Andres Jan, Bernemann, Christof, Schlack, Katrin

Additional file 1: Figure S1. Cell lines at different stages of prostate cancer. Schematic overview of the clinical course of prostate cancer from healthy epithelium (left) to end stage prostate cancer and representative, established prostate (cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ee93a5a3ecc9b51664e5a1c9a254606

Additional file 6 of Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer

Autor: Wüstmann, Neele, Seitzer, Konstantin, Humberg, Verena, Vieler, Julia, Grundmann, Norbert, Steinestel, Julie, Tiedje, Dorothee, Duensing, Stefan, Krabbe, Laura-Maria, Bögemann, Martin, Schrader, Andres Jan, Bernemann, Christof, Schlack, Katrin

Additional file 6: Table S3. Univariate analyses of biomarkers for PFS and OS in 65 mCRPC-patients on abiraterone or enzalutamide therapy (overall cohort). TableS4. Univariate analyses of biomarkers for PFS and OS in 54 mCRPC-patients on abiraterone

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28b6730fb69e49012d47e5119bf67941

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer.

Autor: Wüstmann, Neele, Seitzer, Konstantin, Humberg, Verena, Vieler, Julia, Grundmann, Norbert, Steinestel, Julie, Tiedje, Dorothee, Duensing, Stefan, Krabbe, Laura-Maria, Bögemann, Martin, Schrader, Andres Jan, Bernemann, Christof, Schlack, Katrin

Publikováno v: Biomarker Research; 4/5/2023, Vol. 11 Issue 1, p1-14, 14p